Navigation Links
Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
Date:4/4/2013

Norwood, MA (PRWEB) April 04, 2013

Infinata, part of the Financial Times Group of companies, is a leading provider of business intelligence solutions including BioPharm Insight™, BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. Today the company announced the launch of its corporate-wide Clear Quality initiative to optimize reliability and usability of its cloud-based solutions.

With more than 250 individual quality checks and processes, Clear Quality formalizes Infinata’s commitment to ensuring every one of its hundreds of thousands of data points is as current and accurate as possible for three primary goals:

  •     Data Integrity – Underlying internal and external data sources are current and accurate, ensuring reliable reports and up-to-date analysis
  •     Consistency – Results and recommendations from diverse searches reach uniform conclusions and are presented in a familiar manner for a seamless user experience
  •     Accessibility – Our streamlined and intuitive interface is constantly refined to reduce the number of clicks from a customer’s inquiry to an actionable result

“Infinata was founded over a decade ago by data aggregation and integration experts,” said Ruth McHenry, Managing Director of Infinata. “As the big data requirements of global biopharmaceutical and financial services industries mature, simply providing data is no longer sufficient. Infinata stays ahead of this curve by innovating with services, features and analysis which provide practical answers based on trustworthy data rather than ambiguous facts and figures.”

Continued McHenry, “Clear Quality is a robust, formal and transparent commitment to customers who rely on Infinata solutions for the information edge they need to gain a competitive advantage and dominate their global markets.”

To learn more about Infinata’s solutions, visit http://www.infinata.com.

About Infinata, Inc.

Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, part of the Financial Times Group of companies and a division of Pearson plc.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10599354.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
5. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
6. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
7. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
8. Northwest Bio Implements Major Balance Sheet Clean-Up
9. Clinilabs Launches Research Volunteer Authentication Initiative Choosing Verified Clinical Trials to Stop Dual Enrollment in Clinical Trials
10. Strategic Approach for R&D Is Goal at National Photonics Initiative Event Co-Sponsored by SPIE
11. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which ... today to pursue the highest level of accuracy and quality with the addition ... and the AR5 Refractometer. Accurate, reliable and tough enough for the most ...
(Date:2/10/2016)... BioAmber Inc. (NYSE: BIOA ), a leader in ... Co. Ltd., its partner in the Sarnia ... additional CDN$25 million in the joint venture for 10% ... 40%.  Mitsui will also play a stronger role in ... Sarnia , providing dedicated resources alongside BioAmber,s commercial ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology:
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):